Alemtuzumab for Multiple Sclerosis.

Curr Neurol Neurosci Rep · 2016 · PMC4971037 · PMID 27485945

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not achieve significanceno p-value reported

a worsening of 0.24 in the interferon beta 1-a group), both groups experienced an improvement in EDSS in CARE-MSI (improvement of 0.14 points in both groups), which did not achieve significance [ 7 , 8 ].

also in 1,397 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.